

# Sulfated Galactofucans

Subjects: **Others**

Contributor: Ahmed Zayed , Jose Avila-Peltroche , Mona El-Aasr , Roland Ulber

Fucoidans encompass versatile and heterogeneous sulfated biopolysaccharides of marine origin, specifically brown algae and marine invertebrates. The reported studies revealed diverse chemical skeletons in which L-fucose is the main sugar monomer. However, other sugars, i.e., galactose, mannose, etc., have been identified to be interspersed, forming several heteropolymers, including galactofucans/fucogalactans (G-fucoidans). Particularly, sulfated galactofucans are associated with rich chemistry contributing to more promising bioactivities than fucans and other marine polysaccharides. The previous reports showed that G-fucoidans derived from *Undaria pinnatifida* were the most studied; 21 bioactivities were investigated, especially antitumor and antiviral activities, and unique biomedical applications compared to other marine polysaccharides were demonstrated.

bioactives

brown seaweeds

fucoidans

heteropolysaccharides

structural features


sulfated galactofucans

## 1. Introduction

Fucoidans are unique products of marine organisms, specifically sulfated polysaccharides derived from brown algae and marine invertebrates [1]. They have gained great interest in the last few decades from different fields of sciences, including chemistry, biology, medicine, nutrition, and formulations [2][3][4][5]. All this interest is attributed to the diverse physicochemical, chemical, and biological characteristics [6][7]. These characteristics are relatively related to each other and have been studied previously in a wide variety of literature [8][9][10][11][12][13]. Hence, biological investigations are always performed after full chemical and physicochemical characterizations of purified fucoidans [14][15][16][17]. Monosaccharide composition, molecular weight, sulfation pattern, and sulfation content were found to be the most predominant factors that contribute to fucoidans' molecular mechanisms [11][12][18][19].

The aforementioned characteristics of fucoidans were demonstrated to be highly dependent on many factors, including downstream processes such as extraction either by classical solvent or non-conventional extraction methods [20][21][22], fractionation and purification methods [23][24][25], biogenic sources [24][26][27], and season of harvesting [28]. For instance, fucoidans isolated from sea cucumber showed a homogeneous chemical structure in comparison with brown seaweeds [27]. All of these factors have contributed to the chemical diversity and complexity of fucoidans, the lack of reproducibility of investigational results, and the difficulty of their approval by drug authorities and clear understanding of structure-activity relationships [29].

The chemical diversity of fucoidans has resulted in various backbones that can be classified according to monomeric composition into sulfated fucans (F-fucoidans), galactofucans/fucogalactans (G-fucoidans or G-fucans), fucomannoglucuronans (GA or U-fucoidans), and others [10][30][31][32]. Representative examples are demonstrated in **Figure 1**.



**Figure 1.** Different chemical backbones of fucoidans isolated from marine seaweeds in which  $\alpha$ -L-fucopyranosyl residue (Fucp) is the major sugar monomer. **(A)** A sulfated fucan (F-fucoidans) isolated from *Lessonia* sp., where the Fucp monomers are linked by  $\alpha$ (1 $\rightarrow$ 3) and sulfated at O-4 and partially at O-2 [30]. **(B)** A sulfated galactofucan (G-fucoidans) isolated from *Hormophysa cuneiformis*.  $\beta$ -D-Galactopyranosyl residues (Galp) are found mostly at the periphery of molecules as (1 $\rightarrow$ 6)-linked (R=H or SO<sub>3</sub><sup>-</sup>) [32]. **(C)** Fucoidan containing uronic acid at O-2 isolated from *Cladosiphon okamuranus* [33]. **(D)** A sulfated xylofucan from *Punctaria plantaginea*.  $\beta$ -D-Xylopyranosyl residues (R=H or Xylp) randomly substitute Fucp monomers at O-4 [34].

## 2. Occurrence, Distribution, and Chemistry


Brown seaweeds, in contrast to marine invertebrates, can synthesize more complicated, diverse, and heterogeneous fucoidan backbones, including glycosidic linkages, monomeric composition, and branching sites [35][36][37]. Therefore, various G-fucoidans with different fucose:galactose ratios have been reported in the different brown algae orders, including Fucales, Laminariales, and Dictyales [38][39].

Traces of other sugars may be found, as in the case of *Dictyota menstrualis* [40] and *Sargassum* sp. [41]. Nevertheless, the presence of high percentages of glucose, i.e., fucose:galactose:glucose ratio of 1:0.3:0.25, may indicate contamination of the

G-fucoidan with laminarin [42]. In such cases, fucoidans are partially purified by ethanol or cetyltrimethylammonium bromide (CTAB) precipitation and not purified by a specific chromatographic method, including anion exchange resin using diethylaminoethyl cellulose (DEAE-C) [43] or affinity chromatography [44].

In addition, previous studies, with the aid of advanced spectral analyses, i.e., 2D NMR (e.g., HMQC, TOCSY, and NOESY) and mass spectrometry, have attempted to reveal many structural features of G-fucoidans of various biogenic sources, including glycosidic linkages, sugar configuration, branching sites, sulfation pattern, and galactose position [6][45][46]. In addition, they could deduce tentative structure bioactivity relationships, as in the case of the anti-inflammatory mechanism of galactofucan isolated from *Saccharina japonica* [47].

The results of spectral analyses showed that  $\alpha$ -L-fucopyranose (Fucp) and  $\beta$ -D-galactopyranose (Galp) are identified mainly, in which Fucp forms the major backbone and is linked via (1→4) and/or (1→3), while the  $\beta$ -D-galactopyranose molecules are found at branching sites, usually at (1→6), as in case of the G-fucoidan isolated from *Hormophysa cuneiformis*. In addition, the sulfation pattern is variable based on the glycosidic linkages. For instance, sulfate groups may occupy 2-O and 4-O in  $\rightarrow$ 3Fucp1 $\rightarrow$  or 2-O and 3-O in  $\rightarrow$ 4Fucp1 $\rightarrow$ , in addition to 2-O in  $\rightarrow$ 3,4Fucp1 $\rightarrow$  [32]. Other models of sulfated galactofucans derived from *Sargassum thunbergii* were found to possess  $\rightarrow$ 3Fucp1 $\rightarrow$  as a main backbone with a 2-O-sulfated and 2,4-O-disulfated pattern, while the Galp residues interspersed Fucp in the main chain were linked mainly with  $\rightarrow$ 6Galp1 $\rightarrow$  and 4-O sulfation [48]. Moreover, G-fucoidan isolated from *S. polycystum* was built up mainly of a 4-O sulfated  $\rightarrow$ 3Fucp1 $\rightarrow$  backbone containing single  $\rightarrow$ 2Galp1 $\rightarrow$  residues sulfated similarly at the 4-O position [49]. Several other models are demonstrated in **Figure 2** and **Table 1** and in relation to their biomedical applications.



**Figure 2.** Structure models of sulfated galactofucans isolated from brown algae showing several possibilities of glycosidic linkages and sulfation patterns.

**Table 1.** Marine species of brown macroalgae (Phaeophyceae) producing G-fucoidans highlighting various structural features.

Brown Algae (Seaweed) Species	Source of Seaweed Biomass	Structural Characteristics						References
		Monosaccharide Composition	Glycosidic Bonds of Backbone	Molecular Weight (kDa)	Fucose/Galactose Ratio	Sulfate Content (%)	Sulfation Pattern	
<b>Dictyotales</b>								
Canistrocarpus cervicornis	Wild	Gal, fuc, glcAc, xyl,		ND	2	16.5	ND	[50]
Dictyota dichotoma	Wild	Gal, fuc, man, xyl, ara, rha, glc		23.6	1.5	33	ND	[51]
D. implexa	Wild	Gal, fuc		ND	1	18.3	ND	[52]

Brown Algae (Seaweed) Species	Source of Seaweed Biomass	Structural Characteristics						References
		Monosaccharide Composition	Glycosidic Bonds of Backbone	Molecular Weight (kDa)	Fucose/Galactose Ratio	Sulfate Content (%)	Sulfation Pattern	
<i>Lobophora variegata</i>	Wild	Gal, fuc, Glc, man, xyl, glcAc; Gal, fuc; Gal, fuc, Glc	(1,3)- and (1,4)- $\alpha$ -l-fuc, and (1,3)- $\beta$ -d-gal	35; ND; 1400	0.79; 0.5; 0.5	32.6; 0.2 *;15	At C4 (fuc)	[53][54]
<i>L. variegata</i>	ND	Gal, fuc	ND	360– 1600	0.3	23.3– 35.5	ND	[55]
<i>Padina boryana</i>	Wild	Gal, fuc	(1,4)- $\alpha$ -l-fuc, and (1,3)- $\beta$ -d-gal	317.5/8.5	1.1	18.6	At C2 and C4 (fuc and gal)	[56]
<i>Spatoglossum schroederi</i>	Wild	Gal, fuc, xyl, glcAc; Gal, fuc, xyl;	(1,4)- $\beta$ -d- gal, (1,4)- $\alpha$ -l- fuc, and (1,4)- $\beta$ -d-xyl	21.5; 21.5–24	0.5; 0.5	19; 2.1–2.9 *	At C3 (gal) and C4 (fuc)	[57][58][59][60]
<b>Ectocarpales</b>								
<i>Adenocystis utricularis</i>	Wild	Gal, fuc, rha, man; Gal, fuc, rha; Gal, fuc, man	(1,3)- $\alpha$ -l-fuc	>100	5.53; 4.82; 5.53	23; 24; 23	At C4 (fuc and gal)	[61][62]
<i>Scytosiphon lomentaria</i>	Wild	Gal, fuc, rha, xyl, man, uronic acid	(1,3)- $\alpha$ -l- fuc, and (1,6)- $\beta$ -d-gal	8.5	7.33	29.5	At C3 and C4 (fuc), and C3 (gal)	[63]
<b>Fucales</b>								
<i>Cystoseira compressa</i>	Wild	Gal, fuc	(1,3)- and (1,4)- $\alpha$ -l-fuc	100	2.32	14.7	At C2 and C4 (fuc)	[46]
<i>Sargassum duplicatum</i>	Wild	Gal, fuc	(1,4)- $\alpha$ -l-fuc and $\beta$ -d-gal (alternating)	34–191	1	31.7	ND	[14]
<i>S. feldmannii</i>	Wild	Gal, fuc	(1,3)- $\alpha$ -l-fuc	183–184	2–2.6	25.3–32	At C2, C3 and C4 (fuc), and C2, C3, C4 and C6 (gal)	[14][64]

Brown Algae (Seaweed) Species	Source of Seaweed Biomass	Structural Characteristics						References
		Monosaccharide Composition	Glycosidic Bonds of Backbone	Molecular Weight (kDa)	Fucose/Galactose Ratio	Sulfate Content (%)	Sulfation Pattern	
<i>S. fusiforme</i>	Wild	Gal, fuc, xyl, Glc, glcAc, man, uronic acid; Gal, fuc, xyl, man, rha, glcAc, Glc	(1,3)- and (1,4)- $\alpha$ -l-fuc	90; 118.3/3.9	2; 3.7	17.5; 28.5	At C3 (fuc)	[65][66]
<i>S. hemiphyllum</i>	Wild	Gal, fuc	(1,6)- $\beta$ -d- gal, (1,3)- and (1,4)- $\alpha$ -l- fuc, and (1,3)- $\beta$ -d-gal	148	4.5	32	At C2 and C4 (fuc)	[67]
<i>S. mcclurei</i>	Wild	Gal, fuc; Gal, fuc, man, xyl, glc	(1,3)- $\alpha$ -l-fuc	ND	1.4; 2	35; 30.5	At C2 and C4 (fuc)	[68][69]
<i>S. patens</i>	Wild	Gal, fuc, man, xyl, Glc, galactosamine	ND	424	1.9	14.4	ND	[70][71][72]
<i>S. polycystum</i>	Wild	Gal, fuc, glc; Gal, fuc, man, xyl, glc	(1,3)- $\alpha$ -l- fuc, and (1,6)- $\beta$ -d-gal	39.5; ND	5.84; 1.48	33.6; 23.4	At C2 and C4 (fuc)	[69][73]
<i>S. siliquosum</i>	Wild	Gal, fuc, glc, xyl, man, rha; Gal, fuc, Glc, xyl, man, rha, uronic acid	(1,3)- and (1,4)- $\alpha$ -l-fuc	107.3; ND	1.9; 1.9	19.5; 20	At C4 and C6 (gal)	[10][74]
<i>S. thunbergii</i>	Wild	Gal, fuc	(1,3)- $\alpha$ -l-fuc	7.2- 333.5	5.26-5.88	27.2- 30.1	At C2 and C4 (fuc), and C4 (gal)	[45][48]
<i>S. thunbergii</i>	Purchased from local store	Gal, fuc	(1,4)- $\alpha$ -d- gal, and (1,3)- $\beta$ -l-fuc	373	1.2	ND	NA	[75]
<i>S. wightii</i>	Wild	Gal, fuc, Glc, man; Gal, fuc	(1,3)- $\alpha$ -l-fuc	>3.5; ND	0.6; 3-3.5	379.1 <sup>†</sup> ; 8.1- 19.5	At C2 and/or C4 (fuc), or C2 and C3 (gal)	[76][77][78]

Brown Algae (Seaweed) Species	Source of Seaweed Biomass	Structural Characteristics					Sulfate Content (%)	Sulfation Pattern	References
		Monosaccharide Composition	Glycosidic Bonds of Backbone	Molecular Weight (kDa)	Fucose/Galactose Ratio				
<i>Turbinaria ornata</i>	Wild	Gal, fuc; Gal, fuc, man, xyl, glc	(1,3)- $\alpha$ -l-fuc	ND	5; 1.2	32; 25.6	At C2 and/or C4 (fuc), and/or C2, C3, C4/C6 (gal)	[69][79]	
<b>Laminariales</b>									
<i>Alaria angusta</i>	Wild	Gal, fuc	(1,3)- $\alpha$ -l-fuc	ND	1.1	24	At C2 (fuc), and C2 and C4 (gal)	[80]	
<i>Costaria costata</i>	Wild	Gal, fuc, man, rha, xyl	ND	ND	1.2	18.9	ND	[81]	
<i>Ecklonia cava</i>	Wild	Gal, fuc, man, rha; Gal, fuc, rha, glc	ND	ND	4.8; 3.6	19.1; 22.2	At C2 (fuc)	[81]	
<i>Laminaria hyperborea</i>	ND	Gal, fuc	(1,3)- $\alpha$ -l-fuc	469	44.5	53.8	At C2 and C4 (fuc)	[12]	
<i>Saccharina angustata</i>	Wild	Gal, fuc, xyl, uronic acid	(1,3)-, (1,4) and (1,2)- $\alpha$ -l-fuc	56	9.1	4.2	At C4 (fuc and gal)	[82]	
<i>S. gurjanovae</i>	Wild	Gal, fuc	(1,3)- $\alpha$ -l-fuc	123	3.2	25.1	At C2 and C4 (fuc), and C2 and/or C3 (gal)	[83]	
<i>S. japonica</i>	Wild	Gal, fuc; Gal, fuc, man, xyl; Gal, fuc, man, rham, xyl; Gal, fuc, uronic acid, man, glcAc; Gal, fuc, Glc, man, rha, xyl; Gal, fuc, xyl, Glc, glcAc, rha, uronic acid	(1,3)- $\alpha$ -l-fuc	195/13.7; 1800; ND; 106.3; 23.5; 11	3.6; 1.1; 1.8; 9.1; 0.5; 10	21; 23.3; 23; 36.9; 18; 41.3	At C2 and C2/C4 (fuc)	[66][84][85][86][87]	

Brown Algae (Seaweed) Species	Source of Seaweed Biomass	Structural Characteristics						References
		Monosaccharide Composition	Glycosidic Bonds of Backbone	Molecular Weight (kDa)	Fucose/Galactose Ratio	Sulfate Content (%)	Sulfation Pattern	
<i>S. japonica</i>	Cultivated	Gal, fuc; Gal, fuc, man, rham, xyl, Glc; Gal, fuc, man, Glc, rha, xyl, uronic acid	(1,3)- and (1,4)- $\alpha$ -l-fuc	261.7; 131.5; 8.1	3.8; 2.1; 5.8	11.4; 9.1; 41.8	At C4 (fuc)	[47][88][89]
<i>S. japonica</i>	Provided by Fujian Yida Food Co.	Gal, fuc, man	ND	527.3	0.9	26.7	ND	[90]
<i>S. japonica</i>	ND	Gal, fuc	(1,3)- $\alpha$ -l- fuc, and (1,6)- $\beta$ -d-gal	>10	3.5	48.3	At C4 and/or C2/C4 (fuc), and C4 and/or C3/C4 (gal)	[91]
<i>S. latissima</i>	Wild	Gal, fuc; Gal, fuc, xyl, man, Glc	(1,3)- $\alpha$ -l-fuc	416-449; 453	7.8; 4.1	0.8 ‡; 0.6 †	ND	[92][93]
<i>S. longicuris</i>	Wild	Gal, fuc, xyl, man, Glc, glcAc; Gal, fuc, xyl, man, Glc, galAc, glcAc		1529; 638	0.8; 0.4	17.6; 19.1	At C4 (fuc), and C3 (gal)	[94]
<i>Undaria pinnatifida</i>	Wild	Gal, fuc, man; Gal, fuc, rha; Gal, fuc, Glc, man, rha, xyl, ara	(1,3)- or (1,4)- $\alpha$ -l-fuc	ND; 290; ND	1.1; 1.2; 1.3	29; 0.94 ‡; ND	At C2, C3, C4 (fuc), or C2 and C4 (fuc and/or gal)	[84][95][96]
<i>U. pinnatifida</i> (sporophylls)	Wild	Gal, fuc, xyl, man	(1,3)- $\alpha$ -l-fuc	>150	1.5	15	ND	[97][98]
	Cultivated	Gal, fuc; Gal, fuc, man; Gal, fuc, xyl, man; Gal, fuc, man, xyl, uronic acid	(1,3)- $\alpha$ -l- fuc, and (1,3)-, (1,4)- , (1,6)- $\beta$ -d- gal	ND; 1.4- 3.7; 1246; 2100	1.4; 1.1; 1.1; 5	31; 8.4; 9.2; 7.4	At C2/C4 (fuc), and C3/C6 (gal)	[99][100][101]
<i>U. pinnatifida</i> (sporophylls)	From mussel farms	Gal, fuc, xyl, Glc, man; Gal, fuc, xyl, Glc, man, uronic acid		171; >150	1.5; 1.5	15; 15	ND	[102][103]

Brown Algae (Seaweed) Species	Source of Seaweed Biomass	Structural Characteristics						References
		Monosaccharide Composition	Glycosidic Bonds of Backbone	Molecular Weight (kDa)	Fucose/Galactose Ratio	Sulfate Content (%)	Sulfation Pattern	
U. pinnatifida	From Marine Resources Pty Ltd.			ND	ND	ND	ND	[104]
	From Marinova Pty Ltd.	Gal, fuc, xyl, man	(1,3)- $\alpha$ -l-fuc	51.7	1.3	21.5	At C2 and C4 (fuc)	[105]
U. pinnatifida (sporophylls)	ND			ND	ND	ND	ND	[106]
	ND	Gal, fuc; Gal, fuc, uronic acid; Gal, fuc, xyl, man	(1,3)- $\alpha$ -l-fuc, and (1,3)-, (1,4)-, (1,6)- $\beta$ -d-gal	9; 9; 104.4	0.9; 0.9; ND	10.4; 10.4; 21	At C2 (fuc), and C3 and C6 (gal)	[107][108][109]
<b>Sphacelariales</b>								
Sphacelaria indica	Wild	Gal, fuc, xyl, man, Glc	(1,3)- $\alpha$ -l-fuc	26	3.3	4	At C4 (fuc)	[110]

ND, not detailed; NA, not applicable; \* reported as molar ratio to fucose; † reported as mg/g fucoidan; ‡ reported as degree of sulfation.

## 3. Potential Pharmacological Activities

### 3.1. Anticancer/Antitumor Activity

Several studies have reported the anticancer/antitumor activities of galactofucans in different cancer cell lines, as well as antiproliferative, antimetastasis, and antiangiogenic effects (**Table 2**).

**Table 2.** G-fucoidans showing anticancer/antitumor activity with their respective sources and half-maximal inhibitory concentrations (IC<sub>50</sub>). Comparisons with standard or commercial compounds are also shown.

Source	IC <sub>50</sub>	Compared with Standard/Commercial Compounds?	References
Saccharina latissima	0.35 $\mu$ g/mL (elastase inhibition)	Yes. Superior to commercial heparins (UFH and tinzaparin)	[92]
Sargassum polycystum	84.63 $\mu$ g/mL (leukemia cells) and 93.62 $\mu$ g/mL (breast cancer cells)	No	[69][73]
S. thunbergii	29.7–93.5 $\mu$ g/mL (inhibition of FGF1 binding) and 4.0–6.8 $\mu$ g/mL (inhibition of FGF7 binding)	No	[45][48]
Undaria pinnatifida (sporophylls)	0.10 mg/mL (breast adenocarcinoma) and 0.15 mg/mL (lung carcinoma)	Yes. Superior to commercial fucoidan from Fucus for both cancer cell lines	[102][103][111]

### 3.2. Antiviral Activity

Galactofucans show antiviral properties against a number of highly pathogenic viruses, including the human immunodeficiency

virus (HIV-1) (Table 3).

**Table 3.** Summarized antiviral activity of G-fucoidans with their respective sources and half-maximal effective or inhibitory concentrations (EC<sub>50</sub>/IC<sub>50</sub>). Comparisons with antiviral drugs are also shown.

Source	EC <sub>50</sub> /IC <sub>50</sub>	Compared with Antiviral Drugs?	References
Adenocystis utricularis	0.6–0.9 µg/mL (HIV-1)	Yes. Superior to azidothymidine	[61][62]
	0.3 µg/mL (HSV-1) and 0.5 µg/mL (HSV-2)	No	[61]
Dictyota dichotoma	7.5 µg/mL (HSV-1), and 15.6 µg/mL (CVB3)	Yes. Superior to ribavirin	[51]
Saccharina japonica	0.001–0.005 µg/mL (HIV-1)	No	[85]
	0.2–25 µg/mL (HSV-1)	Yes. Inferior to acyclovir and similar to heparin	[82]
Sargassum mcclurei	0.96 µg/mL (HIV-1)	Yes. Inferior to AMD3100 (plerixafor)	[69]
S. patens	1.3 µg/mL (HSV-2), 5.5 µg/mL (HSV-1), and 4.1 µg/mL (HSV-1 acyclovir-resistant strain)	No	[70][71][72]
	>50 µg/mL (virucidal activity against HSV-2), 1.3–1.65 µg/mL (plaque formation), 1.85–3.5 µg/mL (inhibition of virus adsorption)	No	
	1.5–5.5 mg/mL (HSV-1 replication) and 3–4 mg/mL (HSV-1 adsorption)	Yes. Similar to acyclovir	
S. polycystum	0.34 µg/mL (HIV-1)	Yes. Inferior to AMD3100 (plerixafor)	[69]
Scytosiphon lomentaria	0.76 µg/mL (HSV-1) and 1.34 µg/mL (HSV-2)	No	[63]
Sphacelaria indica	1.3 µg/mL (HSV-1)	Yes. Superior to acyclovir when added to the overlay medium after penetration of the viruses into the host cell	[110]
Turbinaria ornata	0.39 µg/mL (HIV-1)	Yes. Inferior to AMD3100 (plerixafor)	[69]
Undaria pinnatifida	0.77 µg/mL (HSV-1)	Yes. Superior to acyclovir	[96]
	32 µg/mL (HSV-1) and 0.5 µg/mL (HSV-2)	Yes. Superior to acyclovir	[106]
U. pinnatifida (sporophylls)	2.5 µg/mL (HSV-1), 2.6 µg/mL (HSV-2), and 1.5 µg/mL (HCMV)	No	[107][108][109]
U. pinnatifida	1.1 µg/mL (HSV-1), 0.1 µg/mL (HSV-2), and 0.5 µg/mL (HCMV)	No	[84][95][96]
	3.1 µg/mL (HSV-1) and 1.6 µg/mL (HSV-2)	No	[104]



### 3.3. Anti-Inflammatory, Immunomodulatory, and Anticomplement Activities

Jin et al. have studied different factors that may affect the anticomplement activity of G-fucoidans. Among them were extraction methods, molecular weight, fucose:galactose molar ratio, sulfate content, uronic acid, type of glycosidic linkage, branching, and monomeric composition. The study concluded that larger molecular weights were more related to better activities [66]. G-fucoidans might also represent a novel and safer treatment strategy for chronic inflammation or related ailments. Six brown algal species have shown promising anti-inflammatory effects. Galactofucans from *Sargassum wightii* showed superior activity to aspirin, with EC<sub>90</sub> values ranging from 0.2 to 1.22 mg/mL for inhibition of inflammatory-related enzymes [77][78]. Only the galactofucans from *Saccharina japonica* and *Lobophora variegata* have been tested in vivo with positive results [47][53][54][89]. Chen et al. showed that the investigated galactofucans from *S. japonica* were non-cytotoxic in the range of 3.125 to 25 µg/mL [47]. The anti-inflammatory was investigated in the form of fucoidan-based cream using fucoidan derived from *F. vesiculosus* of fucose:galactose ratio 1.0:0.05.

### 3.4. Anticoagulant and Antithrombotic Activities

Fucoidans are well-known for their anticoagulant and antithrombotic activities. These polysaccharides have attracted extensive interest in discovering safer anticoagulants, with less hemorrhagic risk and good antithrombotic activity [112]. As part of this complex class of molecules, G-fucoidans also represent a source of potential antithrombotic drugs. For example, a sulfated galactofucan from *Spatoglossum schroederi* was 2-fold more potent than heparin in stimulating the synthesis of antithrombotic heparan sulfate by endothelial cells of rabbit aorta. In vivo experiments were key to clarifying the antithrombotic activity of this galactofucan, which initially did not show an anticoagulant effect during in vitro experiments. Such an effect was demonstrated for the fraction C at 100 µg/mL with an MW of 24 kDa [57]. Fucoidans can also enhance the plasma level of recombinant tissue plasminogen activator (rtPA), a protein commonly used as a non-interventional treatment to recanalize vessels occluded by acute thrombosis.

### 3.5. Antioxidant Activity

The scavenging effect of fucoidans on harmful oxidants, such as superoxide anion, hydrogen peroxide, hydroxyl radicals, and singlet oxygen, has attracted considerable interest from the food and pharmaceutical industries [113]. In this regard, galactofucan from the Tunisian brown seaweed *Cystoseira compressa* exhibited valuable antioxidant properties when subjected to various antioxidant tests, i.e., ferrous ion chelation, ferric ion reduction, and DPPH radical scavenging assays (Table 4). For instance, the DPPH assay resulted in an IC<sub>50</sub> value of 430 µg/mL compared to 560 µg/mL for sodium alginate isolated from the same organism [46].

**Table 4.** G-fucoidans showing antioxidant activity with their respective sources and half-maximal effective or inhibitory concentrations (EC<sub>50</sub>/IC<sub>50</sub>). Comparisons with standard or commercial compounds are also shown.

Source	EC <sub>50</sub> /IC <sub>50</sub>	Compared with Standard/Commercial Compounds?	References
<i>Cystoseira compressa</i>	0.43 mg/mL (DPPH)	Yes. Inferior to ascorbic acid and butylated hydroxyanisole	[46]
<i>Sargassum siliquosum</i>	2.58 mg/mL (DPPH)	No	[10]
<i>S. thunbergii</i>	0.22 mg/mL (superoxide radical), and 0.88 mg/mL (hydroxyl radical)	Yes. Similar (hydroxy radical) or superior (superoxide radical) to vitamin C	[75]

### 3.6. Other Biological Activities

Two recent studies have reported that galactofucans from *Sargassum siliquosum* exhibited antilipogenesis properties. According to the authors, the purified G-fucoidans (80 µg/mL) from this species induced a 28.9% reduction in lipid synthesis in human hepatoma cell line HepG2 after being induced by lipid accumulation with 1.0 mM oleate. The study used pioglitazone as a positive control at a concentration of 40 µg/mL [10][74]. In addition, the hypolipidemic effect was reported for a sulfated galactofucan from *Saccharina japonica* via inhibition of pancreatic lipase activity in a dose-dependent manner. Interestingly, this polysaccharide was not degraded by the human digestive system, likely due to its high molecular weight. Hence, this research might correlate such bioactivity not to the systemic effect, but through modulation of the microbiota composition. These results suggested that galactofucans could serve as fat-reducing health supplements without affecting the total sugar level [90].

Other properties reported for G-fucoidans, such as elastase inhibition and neuron protection activities, might be correlated to other well-studied activities (e.g., antitumor, antioxidant, or anti-inflammatory) [88][93]. Moreover, Pozharitskaya et al. used a G-fucoidan isolated from *F. vesiculosus*, revealing its anti-hyperglycemic activity based on its inhibition of dipeptidyl peptidase-IV (DPP-IV) at IC<sub>50</sub> 1.11 µg/mL [114].

---

## References

1. Zayed, A.; Ulber, R. Fucoidans: Downstream processes and recent applications. *Mar. Drugs* 2020, 18, 170.
2. Tanna, B.; Mishra, A. Nutraceutical potential of seaweed polysaccharides: Structure, bioactivity, safety, and toxicity. *Compr. Rev. Food Sci. Food Saf.* 2019, 18, 817–831.
3. Alves, C.; Silva, J.; Pinteus, S.; Gaspar, H.; Alpoim, M.C.; Botana, L.M.; Pedrosa, R. From marine origin to therapeutics: The anti tumor potential of marine algae-derived compounds. *Front. Pharmacol.* 2018, 9, 777.
4. Gagliardi, A.; Giuliano, E.; Venkateswararao, E.; Fresta, M.; Bulotta, S.; Awasthi, V.; Cosco, D. Biodegradable polymeric nanop articles for drug delivery to solid tumors. *Front. Pharmacol.* 2021, 12, 601626.
5. Zayed, A.; Haggag, Y.; Ezzat, S.M.; Salem, M.A.; Ulber, R. Fucoidans as nanoparticles: Pharmaceutical and biomedical applicati ons. In *Polysaccharide Nanoparticles*; Venkatesan, J., Kim, S.-K., Anil, S., Rekha, P.D., Eds.; Elsevier: Amsterdam, The Netherla nds, 2022; pp. 413–455.
6. Zayed, A.; El-Aasr, M.; Ibrahim, A.S.; Ulber, R. Fucoidan characterization: Determination of purity and physicochemical and ch emical properties. *Mar. Drugs* 2020, 18, 571.
7. Yang, C.; Chung, D.; Shin, I.S.; Lee, H.; Kim, J.; Lee, Y.; You, S. Effects of molecular weight and hydrolysis conditions on anticanc er activity of fucoidans from sporophyll of *Undaria pinnatifida*. *Int. J. Biol. Macromol.* 2008, 43, 433–437.
8. Zayed, A.; Muffler, K.; Hahn, T.; Rupp, S.; Finkelmeier, D.; Burger-Kentischer, A.; Ulber, R. Physicochemical and biological char acterization of fucoidan from *Fucus vesiculosus* purified by dye affinity chromatography. *Mar. Drugs* 2016, 14, 79.
9. Zayed, A.; Hahn, T.; Finkelmeier, D.; Burger-Kentischer, A.; Rupp, S.; Krämer, R.; Ulber, R. Phenomenological investigation of t he cytotoxic activity of fucoidan isolated from *Fucus vesiculosus*. *Process Biochem.* 2019, 81, 182–187.
10. Wang, S.-H.; Huang, C.-Y.; Chen, C.-Y.; Chang, C.-C.; Huang, C.-Y.; Dong, C.-D.; Chang, J.-S. Structure and biological activity an alysis of fucoidan isolated from *Sargassum siliquosum*. *ACS Omega* 2020, 5, 32447–32455.
11. Li, B.; Lu, F.; Wei, X.; Zhao, R. Fucoidan: Structure and bioactivity. *Molecules* 2008, 13, 1671–1695.
12. Kopplin, G.; Rokstad, A.M.; Mélida, H.; Bulone, V.; Skjåk-Bræk, G.; Aachmann, F.L. Structural characterization of fucoidan from *Laminaria hyperborea*: Assessment of coagulation and inflammatory properties and their structure–function relationship. *ACS Appl. Bio Mater.* 2018, 1, 1880–1892.
13. Abdella, A.A.; Ulber, R.; Zayed, A. Chitosan-toluidine blue beads for purification of fucoidans. *Carbohydr. Polym.* 2020, 231, 1 15686.
14. Usoltseva, R.V.; Anastyuk, S.D.; Surits, V.V.; Shevchenko, N.M.; Thinh, P.D.; Zadorozhny, P.A.; Ermakova, S.P. Comparison of str ucture and in vitro anticancer activity of native and modified fucoidans from *Sargassum feldmannii* and *S. duplicatum*. *Int. J. Biol. Macromol.* 2019, 124, 220–228.
15. Badrinathan, S.; Shiju, T.M.; Sharon Christa, A.S.; Arya, R.; Pragasam, V. Purification and structural characterization of sulfate d polysaccharide from *Sargassum myriocystum* and its efficacy in scavenging free radicals. *Indian J. Pharm. Sci.* 2012, 74, 54 9–555.
16. Usoltseva, R.V.; Anastyuk, S.D.; Shevchenko, N.M.; Surits, V.V.; Silchenko, A.S.; Isakov, V.V.; Zvyagintseva, T.N.; Thinh, P.D.; Er makova, S.P. Polysaccharides from brown algae *Sargassum duplicatum*: The structure and anticancer activity in vitro. *Carboh ydr. Polym.* 2017, 175, 547–556.
17. Lu, J.; Shi, K.K.; Chen, S.; Wang, J.; Hassouna, A.; White, L.N.; Merien, F.; Xie, M.; Kong, Q.; Li, J.; et al. Fucoidan extracted from the New Zealand *Undaria pinnatifida*-physicochemical comparison against five other fucoidans: Unique low molecular weight fraction bioactivity in breast cancer cell lines. *Mar. Drugs* 2018, 16, 461.
18. Bilan, M.I.; Usov, A.I. Structural analysis of fucoidans. *Nat. Prod. Commun.* 2008, 3, 1934578X0800301011.
19. Wang, Y.; Xing, M.; Cao, Q.; Ji, A.; Liang, H.; Song, S. Biological activities of fucoidan and the factors mediating its therapeutic effects: A review of recent studies. *Mar. Drugs* 2019, 17, 183.
20. January, G.G.; Naidoo, R.K.; Kirby-McCullough, B.; Bauer, R. Assessing methodologies for fucoidan extraction from South Afric an brown algae. *Algal Res.* 2019, 40, 101517.
21. Alboofetileh, M.; Rezaei, M.; Tabarsa, M.; Rittà, M.; Donalisio, M.; Mariatti, F.; You, S.; Lembo, D.; Cravotto, G. Effect of different non-conventional extraction methods on the antibacterial and antiviral activity of fucoidans extracted from *Nizamuddinina zan ardinii*. *Int. J. Biol. Macromol.* 2019, 124, 131–137.
22. Nguyen, T.T.; Mikkelsen, M.D.; Tran, V.H.N.; Trang, V.T.D.; Rhein-Knudsen, N.; Holck, J.; Rasin, A.B.; Cao, H.T.T.; Van, T.T.T.; Mey er, A.S. Enzyme-assisted fucoidan extraction from brown macroalgae *Fucus distichus* subsp. *evanescens* and *Saccharina latis sima*. *Mar. Drugs* 2020, 18, 296.
23. Zayed, A.; Dienemann, C.; Giese, C.; Krämer, R.; Ulber, R. An immobilized perylene diimide derivative for fucoidan purification from a crude brown algae extract. *Process Biochem.* 2018, 65, 233–238.
24. Ponce, N.M.A.; Stortz, C.A. A comprehensive and comparative analysis of the fucoidan compositional data across the Phaeop hyceae. *Front. Plant Sci.* 2020, 11, 556312.

25. Sichert, A.; Le Gall, S.; Klau, L.J.; Laillet, B.; Rogniaux, H.; Achmann, F.L.; Hehemann, J.-H. Ion-exchange purification and structural characterization of five sulfated fucoidans from brown algae. *Glycobiology* 2021, 31, 352–357.
26. Cumashi, A.; Ushakova, N.A.; Preobrazhenskaya, M.E.; D’Incecco, A.; Piccoli, A.; Totani, L.; Tinari, N.; Morozevich, G.E.; Berma n, A.E.; Bilan, M.I.; et al. A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds. *Glycobiology* 2007, 17, 541–552.
27. Chang, Y.; Hu, Y.; Yu, L.; McClements, D.J.; Xu, X.; Liu, G.; Xue, C. Primary structure and chain conformation of fucoidan extracted from sea cucumber *Holothuria tubulosa*. *Carbohydr. Polym.* 2016, 136, 1091–1097.
28. Benslim, A.; Sellimi, S.; Hamdi, M.; Nasri, R.; Jridi, M.; Cot, D.; Li, S.; Nasri, M.; Zouari, N. Brown seaweed *Cystoseira schiffneri* as a promising source of sulfated fucans: Seasonal variability of structural, chemical, and antioxidant properties. *Food Sci. Nutr.* 2021, 9, 1551–1563.
29. Zayed, A.; Ulber, R. Fucoidan production: Approval key challenges and opportunities. *Carbohydr. Polym.* 2019, 211, 289–297.
30. Leal, D.; Mansilla, A.; Matsuhira, B.; Moncada-Basualto, M.; Lapier, M.; Maya, J.D.; Olea-Azar, C.; De Borggraeve, W.M. Chemical structure and biological properties of sulfated fucan from the sequential extraction of subAntarctic *Lessonia* sp. (Phaeophyceae). *Carbohydr. Polym.* 2018, 199, 304–313.
31. Berteau, O. Sulfated fucans, fresh perspectives: Structures, functions, and biological properties of sulfated fucans and an overview of enzymes active toward this class of polysaccharide. *Glycobiology* 2003, 13, 29.
32. Bilan, M.I.; Ustyuzhanina, N.E.; Shashkov, A.S.; Thanh, T.T.T.; Bui, M.L.; Tran, T.T.V.; Bui, V.N.; Nifantiev, N.E.; Usov, A.I. A sulfated galactofucan from the brown alga *Hormophysa cuneiformis* (Fucales, Sargassaceae). *Carbohydr. Res.* 2018, 469, 48–54.
33. Ale, M.T.; Mikkelsen, J.D.; Meyer, A.S. Important determinants for fucoidan bioactivity: A critical review of structure-function relations and extraction methods for fucose-containing sulfated polysaccharides from brown seaweeds. *Mar. Drugs* 2011, 9, 2106–2130.
34. Ustyuzhanina, N.E.; Bilan, M.I.; Gerbst, A.G.; Ushakova, N.A.; Tsvetkova, E.A.; Dmitrenok, A.S.; Usov, A.I.; Nifantiev, N.E. Anticoagulant and antithrombotic activities of modified xylofucan sulfate from the brown alga *Punctaria plantaginea*. *Carbohydr. Polym.* 2016, 136, 826–833.
35. Apostolova, E.; Lukova, P.; Baldzhieva, A.; Katsarov, P.; Nikolova, M.; Iliev, I.; Peychev, L.; Trica, B.; Oancea, F.; Delattre, C.; et al. Immunomodulatory and anti-inflammatory effects of fucoidan: A review. *Polymers* 2020, 12, 2338.
36. Hahn, T.; Lang, S.; Ulber, R.; Muffler, K. Novel procedures for the extraction of fucoidan from brown algae. *Process Biochem.* 2012, 47, 1691–1698.
37. Yu, L.; Ge, L.; Xue, C.; Chang, Y.; Zhang, C.; Xu, X.; Wang, Y. Structural study of fucoidan from sea cucumber *Acaudina molpadoides*: A fucoidan containing novel tetrafucose repeating unit. *Food Chem.* 2014, 142, 197–200.
38. Rocha de Souza, M.C.; Marques, C.T.; Guerra Dore, C.M.; Ferreira da Silva, F.R.; Oliveira Rocha, H.A.; Leite, E.L. Antioxidant activities of sulfated polysaccharides from brown and red seaweeds. *J. Appl. Phycol.* 2007, 19, 153–160.
39. Yoon, S.J.; Pyun, Y.R.; Hwang, J.K.; Mourão, P.A. A sulfated fucan from the brown alga *Laminaria cichorioides* has mainly heparin cofactor II-dependent anticoagulant activity. *Carbohydr. Res.* 2007, 342, 2326–2330.
40. Albuquerque, I.R.; Queiroz, K.C.; Alves, L.G.; Santos, E.A.; Leite, E.L.; Rocha, H.A. Heterofucans from *Dictyota menstrualis* have anticoagulant activity. *Braz. J. Med. Biol. Res.* 2004, 37, 167–171.
41. Ale, M.T.; Maruyama, H.; Tamauchi, H.; Mikkelsen, J.D.; Meyer, A.S. Fucoidan from *Sargassum* sp. and *Fucus vesiculosus* reduces cell viability of lung carcinoma and melanoma cells in vitro and activates natural killer cells in mice in vivo. *Int. J. Biol. Macromol.* 2011, 49, 331–336.
42. Palanisamy, S.; Vinosha, M.; Marudhupandi, T.; Rajasekar, P.; Prabhu, N.M. Isolation of fucoidan from *Sargassum polycystum* brown algae: Structural characterization, in vitro antioxidant and anticancer activity. *Int. J. Biol. Macromol.* 2017, 102, 405–412.
43. Je, J.-G.; Lee, H.-G.; Fernando, K.H.N.; Jeon, Y.-J.; Ryu, B. Purification and structural characterization of sulfated polysaccharides derived from brown algae, *Sargassum binderi*: Inhibitory mechanism of iNOS and COX-2 pathway interaction. *Antioxidants* 2021, 10, 822.
44. Hahn, T.; Zayed, A.; Kovacheva, M.; Stadtmüller, R.; Lang, S.; Muffler, K.; Ulber, R. Dye affinity chromatography for fast and simple purification of fucoidan from marine brown algae. *Eng. Life Sci.* 2016, 16, 78–87.
45. Jin, W.; Wu, W.; Tang, H.; Wei, B.; Wang, H.; Sun, J.; Zhang, W.; Zhong, W. Structure analysis and anti-tumor and anti-angiogenic activities of sulfated galactofucan extracted from *Sargassum thunbergii*. *Mar. Drugs* 2019, 17, 52.
46. Hentati, F.; Delattre, C.; Ursu, A.V.; Desbrieres, J.; Le Cerf, D.; Gardarin, C.; Abdelkafi, S.; Michaud, P.; Pierre, G. Structural characterization and antioxidant activity of water-soluble polysaccharides from the Tunisian brown seaweed *Cystoseira Compressa*. *Carbohydr. Polym.* 2018, 198, 589–600.
47. Chen, X.; Ni, L.; Fu, X.; Wang, L.; Duan, D.; Huang, L.; Xu, J.; Gao, X. Molecular mechanism of anti-inflammatory activities of a novel sulfated galactofucan from *Saccharina japonica*. *Mar. Drugs* 2021, 19, 430.
48. Zhang, W.; Wu, W.; Bao, Y.; Yan, X.; Zhang, F.; Linhardt, R.J.; Jin, W.; Mao, G. Comparative study on the mechanisms of anti-lung cancer activities of three sulfated galactofucans. *Food Funct.* 2021, 12, 10644–10657.
49. Bilan, M.I.; Grachev, A.A.; Shashkov, A.S.; Thuy, T.T.; Van, T.T.; Ly, B.M.; Nifantiev, N.E.; Usov, A.I. Preliminary investigation of a highly sulfated galactofucan fraction isolated from the brown alga *Sargassum polycystum*. *Carbohydr. Res.* 2013, 377, 48–5

50. Camara, R.B.; Costa, L.S.; Fidelis, G.P.; Nobre, L.T.; Dantas-Santos, N.; Cordeiro, S.L.; Costa, M.S.; Alves, L.G.; Rocha, H.A. Heterofucans from the brown seaweed *Canistrocarpus cervicornis* with anticoagulant and antioxidant activities. *Mar. Drugs* 2011, 9, 124–138.
51. Rabanal, M.; Ponce, N.M.; Navarro, D.A.; Gomez, R.M.; Stortz, C.A. The system of fucoidans from the brown seaweed *Dictyota dichotoma*: Chemical analysis and antiviral activity. *Carbohydr. Polym.* 2014, 101, 804–811.
52. Shevchenko, N.M.; Usoltseva, R.V.; Ishina, I.A.; Thinh, P.D.; Ly, B.M.; Ermakova, S.P. Structural Characteristics and in vitro Antitumor Activity of Water-Soluble Polysaccharides from Brown Algae of the Russian Far East and Vietnam. *Chem. Nat. Compd.* 2017, 53, 1–5.
53. Medeiros, V.P.; Queiroz, K.C.; Cardoso, M.L.; Monteiro, G.R.; Oliveira, F.W.; Chavante, S.F.; Guimaraes, L.A.; Rocha, H.A.; Leite, E.L. Sulfated galactofucan from *Lobophora variegata*: Anticoagulant and anti-inflammatory properties. *Biochemistry* 2008, 73, 1018–1024.
54. de Sousa Pinheiro, T.; Nascimento Santos, M.D.S.; Will Castro, L.S.E.P.; Paiva, A.A.D.O.; Alves, L.G.; Cruz, A.K.M.; Nobre, L.T.D.B.; Alves, M.G.D.C.F.; Leite, E.L. A fucan of a brown seaweed and its antitumoral property on HT-29 and immunomodulatory activity in murine RAW 264.7 macrophage cell line. *J. Appl. Phycol.* 2017, 29, 2061–2075.
55. Queiroz, K.C.; Assis, C.F.; Medeiros, V.P.; Rocha, H.A.; Aoyama, H.; Ferreira, C.V.; Leite, E.L. Cytotoxicity effect of algal polysaccharides on HL60 cells. *Biochemistry* 2006, 71, 1312–1315.
56. Usoltseva, R.V.; Anastyuk, S.D.; Ishina, I.A.; Isakov, V.V.; Zvyagintseva, T.N.; Thinh, P.D.; Zadorozhny, P.A.; Dmitrenok, P.S.; Ermakova, S.P. Structural characteristics and anticancer activity in vitro of fucoidan from brown alga *Padina boryana*. *Carbohydr. Polym.* 2018, 184, 260–268.
57. Rocha, H.A.; Moraes, F.A.; Trindade, E.S.; Franco, C.R.; Torquato, R.J.; Veiga, S.S.; Valente, A.P.; Mourao, P.A.; Leite, E.L.; Nader, H.B.; et al. Structural and hemostatic activities of a sulfated galactofucan from the brown alga *Spatoglossum schroederi*: An ideal antithrombotic agent? *J. Biol. Chem.* 2005, 280, 41278–41288.
58. Rocha, H.A.; Bezerra, L.C.; de Albuquerque, I.R.; Costa, L.S.; Guerra, C.M.; de Abreu, L.D.; Nader, H.B.; Leite, E.L. A xylogalactofucan from the brown seaweed *Spatoglossum schroederi* stimulates the synthesis of an antithrombotic heparan sulfate from endothelial cells. *Planta Med.* 2005, 71, 379–381.
59. Nobre, L.T.; Vidal, A.A.; Almeida-Lima, J.; Oliveira, R.M.; Paredes-Gamero, E.J.; Medeiros, V.P.; Trindade, E.S.; Franco, C.R.; Nader, H.B.; Rocha, H.A. Fucan effect on CHO cell proliferation and migration. *Carbohydr. Polym.* 2013, 98, 224–232.
60. Menezes, M.M.; Nobre, L.; Rossi, G.R.; Almeida-Lima, J.; Melo-Silveira, R.F.; Franco, C.R.C.; Trindade, E.S.; Nader, H.B.; Rocha, H.A.O. A low-molecular-weight galactofucan from the seaweed, *Spatoglossum schroederi*, binds fibronectin and inhibits capillary-like tube formation in vitro. *Int. J. Biol. Macromol.* 2018, 111, 1067–1075.
61. Ponce, N.M.; Pujol, C.A.; Damonte, E.B.; Flores, M.L.; Stortz, C.A. Fucoidans from the brown seaweed *Adenocystis utricularis*: Extraction methods, antiviral activity and structural studies. *Carbohydr. Res.* 2003, 338, 153–165.
62. Trincherro, J.; Ponce, N.M.; Cordoba, O.L.; Flores, M.L.; Pampuro, S.; Stortz, C.A.; Salomon, H.; Turk, G. Antiretroviral activity of fucoidans extracted from the brown seaweed *Adenocystis utricularis*. *Phytother. Res.* 2009, 23, 707–712.
63. Ponce, N.M.A.; Flores, M.L.; Pujol, C.A.; Becerra, M.B.; Navarro, D.A.; Cordoba, O.; Damonte, E.B.; Stortz, C.A. Fucoidans from the phaeophyta *Scytosiphon lomentaria*: Chemical analysis and antiviral activity of the galactofucan component. *Carbohydr. Res.* 2019, 478, 18–24.
64. Usoltseva, R.V.; Malyarenko, O.S.; Anastyuk, S.D.; Shevchenko, N.M.; Silchenko, A.S.; Zvyagintseva, T.N.; Isakov, V.V.; Thinh, P.D.; Khanh, H.H.N.; Hang, C.T.T.; et al. The structure of fucoidan from *Sargassum oligocystum* and radiosensitizing activity of galactofucans from some algae of genus *Sargassum*. *Int. J. Biol. Macromol.* 2021, 183, 1427–1435.
65. Hu, P.; Li, Z.; Chen, M.; Sun, Z.; Ling, Y.; Jiang, J.; Huang, C. Structural elucidation and protective role of a polysaccharide from *Sargassum fusiforme* on ameliorating learning and memory deficiencies in mice. *Carbohydr. Polym.* 2016, 139, 150–158.
66. Jin, W.; Zhang, W.; Liang, H.; Zhang, Q. The Structure-Activity Relationship between Marine Algae Polysaccharides and Anti-Complement Activity. *Mar. Drugs* 2016, 14, 3.
67. Jin, W.; Fang, Q.; Jiang, D.; Li, T.; Wei, B.; Sun, J.; Zhang, W.; Zhang, Z.; Zhang, F.; Linhardt, R.J.; et al. Structural characteristics and anti-complement activities of polysaccharides from *Sargassum hemiphyllum*. *Glycoconj. J.* 2020, 37, 553–563.
68. Thinh, P.D.; Menshova, R.V.; Ermakova, S.P.; Anastyuk, S.D.; Ly, B.M.; Zvyagintseva, T.N. Structural characteristics and anticancer activity of fucoidan from the brown alga *Sargassum macleurei*. *Mar. Drugs* 2013, 11, 1456–1476.
69. Thuy, T.T.; Ly, B.M.; Van, T.T.; Quang, N.V.; Tu, H.C.; Zheng, Y.; Seguin-Devaux, C.; Mi, B.; Ai, U. Anti-HIV activity of fucoidans from three brown seaweed species. *Carbohydr. Polym.* 2015, 115, 122–128.
70. Zhu, W.; Chiu, L.C.; Ooi, V.E.; Chan, P.K.; Ang, P.O., Jr. Antiviral property and mode of action of a sulphated polysaccharide from *Sargassum patens* against herpes simplex virus type 2. *Int. J. Antimicrob. Agents* 2004, 24, 279–283.
71. Zhu, W.; Chiu, L.C.; Ooi, V.E.; Chan, P.K.; Ang, P.O., Jr. Antiviral property and mechanisms of a sulphated polysaccharide from the brown alga *Sargassum patens* against Herpes simplex virus type 1. *Phytomedicine* 2006, 13, 695–701.
72. Zhu, W.; Ooi, V.E.; Chan, P.K.; Ang, P.O., Jr. Isolation and characterization of a sulfated polysaccharide from the brown alga *Sargassum patens* and determination of its anti-herpes activity. *Biochem. Cell Biol.* 2003, 81, 25–33.
73. Fernando, I.P.S.; Sanjeeva, K.K.A.; Lee, H.G.; Kim, H.S.; Vaas, A.; De Silva, H.I.C.; Nanayakkara, C.M.; Abeyunga, D.T.U.; Lee,

- D.S.; Lee, J.S.; et al. Fucoidan purified from *Sargassum polycystum* induces apoptosis through mitochondria-mediated pathway in HL-60 and MCF-7 cells. *Mar. Drugs* 2020, 18, 196.
74. Wang, S.-H.; Huang, C.-Y.; Chen, C.-Y.; Chang, C.-C.; Huang, C.-Y.; Dong, C.-D.; Chang, J.-S. Isolation and purification of brown algae fucoidan from *Sargassum siliquosum* and the analysis of anti-lipogenesis activity. *Biochem. Eng. J.* 2021, 165, 107798.
75. Luo, D.; Wang, Z.; Nie, K. Structural characterization of a novel polysaccharide from *Sargassum thunbergii* and its antioxidant and anti-inflammation effects. *PLoS ONE* 2019, 14, e0223198.
76. Eluvakkal, T.; Shanthi, N.; Murugan, M.; Arunkumar, K. Extraction of antibacterial substances, galactofucoidan and alginate successively from the Gulf of Mannar brown seaweed *Sargassum wightii* Greville ex J. Agardh. *Indian J. Nat. Prod. Resour.* 2014, 5, 249–257.
77. Maneesh, A.; Chakraborty, K. Pharmacological potential of sulfated polygalactopyranosyl-fucopyranan from the brown seaweed *Sargassum wightii*. *J. Appl. Phycol.* 2018, 30, 1971–1988.
78. Surabhi, G.; Dhara, S.; Maneesh, A.; Chakraborty, K.; Valluru, L.; Chenchula, S.R. Polygalacto-fucopyranose from marine alga as a prospective antihypertensive lead. *Int. J. Biol. Macromol.* 2021, 183, 589–599.
79. Ermakova, S.P.; Menshova, R.V.; Anastyuk, S.D.; Malyarenko, O.S.; Zakharenko, A.M.; Thinh, P.D.; Ly, B.M.; Zvyagintseva, T.N. Structure, chemical and enzymatic modification, and anticancer activity of polysaccharides from the brown alga *Turbinaria ornata*. *J. Appl. Phycol.* 2016, 28, 2495–2505.
80. Menshova, R.V.; Anastyuk, S.D.; Ermakova, S.P.; Shevchenko, N.M.; Isakov, V.I.; Zvyagintseva, T.N. Structure and anticancer activity in vitro of sulfated galactofucan from brown alga *Alaria angusta*. *Carbohydr. Polym.* 2015, 132, 118–125.
81. Ermakova, S.; Sokolova, R.; Kim, S.M.; Um, B.H.; Isakov, V.; Zvyagintseva, T. Fucoidans from brown seaweeds *Sargassum horneryi*, *Eclonia cava*, *Costaria costata*: Structural characteristics and anticancer activity. *Biotechnol. Appl. Biochem.* 2011, 164, 841–850.
82. Saha, S.; Navid, M.H.; Bandyopadhyay, S.S.; Schnitzler, P.; Ray, B. Sulfated polysaccharides from *Laminaria angustata*: Structural features and in vitro antiviral activities. *Carbohydr. Polym.* 2012, 87, 123–130.
83. Shevchenko, N.M.; Anastyuk, S.D.; Menshova, R.V.; Vishchuk, O.S.; Isakov, V.I.; Zadorozhny, P.A.; Sikorskaya, T.V.; Zvyagintseva, T.N. Further studies on structure of fucoidan from brown alga *Saccharina Gurjanovae*. *Carbohydr. Polym.* 2015, 121, 207–216.
84. Vishchuk, O.S.; Ermakova, S.P.; Zvyagintseva, T.N. Sulfated polysaccharides from brown seaweeds *Saccharina japonica* and *Undaria pinnatifida*: Isolation, structural characteristics, and antitumor activity. *Carbohydr. Res.* 2011, 346, 2769–2776.
85. Prokofjeva, M.M.; Imbs, T.I.; Shevchenko, N.M.; Spirin, P.V.; Horn, S.; Fehse, B.; Zvyagintseva, T.N.; Prassolov, V.S. Fucoidans as potential inhibitors of HIV-1. *Mar. Drugs* 2013, 11, 3000–3014.
86. Geng, L.; Hou, N.; Zhang, M.; Xu, Y.; Zhang, Q.; Wang, J.; Zhang, L.; Zhang, Q. Comparative study of the effect of different fucoidans from *Sargassum maclurei* and *Saccharina japonica* on FGFs/FGFR signaling activation in BaF3 cells. *Int. J. Biol. Macromol.* 2018, 107, 2429–2435.
87. Geng, L.; Zhang, Q.; Wang, J.; Jin, W.; Zhao, T.; Hu, W. Glucofucogalactan, a heterogeneous low-sulfated polysaccharide from *Saccharina japonica* and its bioactivity. *Int. J. Biol. Macromol.* 2018, 113, 90–97.
88. Wang, J.; Liu, H.; Jin, W.; Zhang, H.; Zhang, Q. Structure-activity relationship of sulfated hetero/galactofucan polysaccharides on dopaminergic neuron. *Int. J. Biol. Macromol.* 2016, 82, 878–883.
89. Wang, S.; Ni, L.; Fu, X.; Duan, D.; Xu, J.; Gao, X. A Sulfated polysaccharide from *Saccharina japonica* suppresses LPS-induced inflammation both in a macrophage cell model via blocking MAPK/NF- $\kappa$ B signal pathways in vitro and a zebrafish model of embryos and larvae in vivo. *Mar. Drugs* 2020, 18, 593.
90. Zhang, T.; Wu, S.; Ai, C.; Wen, C.; Liu, Z.; Wang, L.; Jiang, L.; Shen, P.; Zhang, G.; Song, S. Galactofucan from *Laminaria japonica* is not degraded by the human digestive system but inhibits pancreatic lipase and modifies the intestinal microbiota. *Int. J. Biol. Macromol.* 2021, 166, 611–620.
91. Dhar, N.; Sarangapani, S.; Reddy, V.A.; Kumar, N.; Panicker, D.; Jin, J.; Chua, N.H.; Sarojam, R. Characterization of a sweet basil acyltransferase involved in eugenol biosynthesis. *J. Exp. Bot.* 2020, 71, 3638–3652.
92. Schneider, T.; Ehrig, K.; Liewert, I.; Alban, S. Interference with the CXCL12/CXCR4 axis as potential antitumor strategy: Superiority of a sulfated galactofucan from the brown alga *Saccharina latissima* and fucoidan over heparins. *Glycobiology* 2015, 25, 812–824.
93. Ehrig, K.; Alban, S. Sulfated galactofucan from the brown alga *Saccharina latissima*—Variability of yield, structural composition and bioactivity. *Mar. Drugs* 2014, 13, 76–101.
94. Rioux, L.-E.; Moulin, V.; Beaulieu, M.; Turgeon, S.L. Human skin fibroblast response is differentially regulated by galactofucan and low molecular weight galactofucan. *Bioact. Carbohydr. Diet. Fibre* 2013, 1, 105–110.
95. Hemmingson, J.A.; Falshaw, R.; Furneaux, R.H.; Thompson, K. Structure and antiviral activity of the galactofucan sulfates extracted from *Undaria Pinnatifida* (Phaeophyta). *J. Appl. Phycol.* 2006, 18, 185–193.
96. Wozniak, M.; Bell, T.; Denes, A.; Falshaw, R.; Itzhaki, R. Anti-HSV1 activity of brown algal polysaccharides and possible relevance to the treatment of Alzheimer's disease. *Int. J. Biol. Macromol.* 2015, 74, 530–540.
97. Teng, H.; Yang, Y.; Wei, H.; Liu, Z.; Liu, Z.; Ma, Y.; Gao, Z.; Hou, L.; Zou, X. Fucoidan suppresses hypoxia-induced lymphangiogenesis and lymphatic metastasis in mouse hepatocarcinoma. *Mar. Drugs* 2015, 13, 3514–3530.

98. Thakur, V.; Lu, J.; Roscilli, G.; Aurisicchio, L.; Cappelletti, M.; Pavoni, E.; White, W.L.; Bedogni, B. The natural compound fucoidan from New Zealand *Undaria pinnatifida* synergizes with the ERBB inhibitor lapatinib enhancing melanoma growth inhibition. *Oncotarget* 2017, 8, 17887.
99. Choi, Y.; Min, S.K.; Usoltseva, R.; Silchenko, A.; Zvyagintseva, T.; Ermakova, S.; Kim, J.K. Thrombolytic fucoidans inhibit the tPA-PAI1 complex, indicating activation of plasma tissue-type plasminogen activator is a mechanism of fucoidan-mediated thrombolysis in a mouse thrombosis model. *Thromb. Res.* 2018, 161, 22–25.
100. Kim, W.-J.; Kim, S.-M.; Kim, H.G.; Oh, H.-R.; Lee, K.-B.; Lee, Y.-K.; Park, Y.-I. Purification and anticoagulant activity of a fucoidan from Korean *Undaria pinnatifida* sporophyll. *Algae* 2007, 22, 247–252.
101. Lee, J.; Lee, S.; Synytsya, A.; Capek, P.; Lee, C.W.; Choi, J.W.; Cho, S.; Kim, W.J.; Park, Y.I. Low molecular weight mannogalactofucans derived from *Undaria pinnatifida* induce apoptotic death of human prostate cancer cells in vitro and in vivo. *Mar. Biotechnol.* 2018, 20, 813–828.
102. Mak, W.; Wang, S.K.; Liu, T.; Hamid, N.; Li, Y.; Lu, J.; White, W.L. Anti-proliferation potential and content of fucoidan extracted from sporophyll of New Zealand *Undaria pinnatifida*. *Front. Nutr.* 2014, 1, 9.
103. Mak, W.; Hamid, N.; Liu, T.; Lu, J.; White, W.L. Fucoidan from New Zealand *Undaria pinnatifida*: Monthly variations and determination of antioxidant activities. *Carbohydr. Polym.* 2013, 95, 606–614.
104. Cooper, R.; Dragar, C.; Elliot, K.; Fitton, J.; Godwin, J.; Thompson, K. GFS, a preparation of Tasmanian *Undaria pinnatifida* is associated with healing and inhibition of reactivation of Herpes. *BMC Complementary Altern. Med.* 2002, 2, 11.
105. Burney, M.; Mathew, L.; Gaikwad, A.; Nugent, E.K.; Gonzalez, A.O.; Smith, J.A. Evaluation fucoidan extracts from *Undaria pinnatifida* and *Fucus vesiculosus* in combination with anticancer drugs in human cancer orthotopic mouse models. *Integr. Cancer Ther.* 2018, 17, 755–761.
106. Thompson, K.D.; Dragar, C. Antiviral activity of *Undaria pinnatifida* against herpes simplex virus. *Phytother. Res. Int. J. Devoted Pharmacol. Toxicol. Eval. Nat. Prod. Deriv.* 2004, 18, 551–555.
107. Lee, J.-B.; Hayashi, K.; Hashimoto, M.; Nakano, T.; Hayashi, T. Novel antiviral fucoidan from sporophyll of *Undaria pinnatifida* (Mekabu). *Chem. Pharm. Bull.* 2004, 52, 1091–1094.
108. Synytsya, A.; Bleha, R.; Synytsya, A.; Pohl, R.; Hayashi, K.; Yoshinaga, K.; Nakano, T.; Hayashi, T. Mekabu fucoidan: Structural complexity and defensive effects against avian influenza A viruses. *Carbohydr. Polym.* 2014, 111, 633–644.
109. Wang, P.; Liu, Z.; Liu, X.; Teng, H.; Zhang, C.; Hou, L.; Zou, X. Anti-metastasis effect of fucoidan from *Undaria pinnatifida* sporophylls in mouse hepatocarcinoma Hca-F cells. *PLoS ONE* 2014, 9, e106071.
110. Bandyopadhyay, S.S.; Navid, M.H.; Ghosh, T.; Schnitzler, P.; Ray, B. Structural features and in vitro antiviral activities of sulfated polysaccharides from *Sphacelaria indica*. *Phytochemistry* 2011, 72, 276–283.
111. Synytsya, A.; Kim, W.-J.; Kim, S.-M.; Pohl, R.; Synytsya, A.; Kvasnička, F.; Čopíková, J.; Il Park, Y. Structure and antitumour activity of fucoidan isolated from sporophyll of Korean brown seaweed *Undaria pinnatifida*. *Carbohydr. Polym.* 2010, 81, 41–48.
112. Wijesinghe, W.A.J.P.; Jeon, Y.-J. Biological activities and potential industrial applications of fucose rich sulfated polysaccharides and fucoidans isolated from brown seaweeds: A review. *Carbohydr. Polym.* 2012, 88, 13–20.
113. Vo, T.-S.; Kim, S.-K. Fucoidans as a natural bioactive ingredient for functional foods. *J. Funct. Foods* 2013, 5, 16–27.
114. Pozharitskaya, O.N.; Obluchinskaya, E.D.; Shikov, A.N. Mechanisms of bioactivities of fucoidan from the brown seaweed *Fucus vesiculosus* L. of the Barents Sea. *Mar. Drugs* 2020, 18, 275.

---

Retrieved from <https://encyclopedia.pub/entry/24682>